

**TORRENT PHARMACEUTICALS LIMITED**

**AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED AND HALF YEAR ENDED ON 30TH SEPTEMBER 2009**

[Rs. in Lacs except per share data]

PARTICULARS	QUARTER ENDED		HALF YEAR ENDED		YEAR ENDED
	30-Sep-09	30-Sep-08	30-Sep-09	30-Sep-08	31-Mar-09
Sales [see note 2]	35337	28057	70506	56380	114827
Less: Excise Duty collected	75	104	153	205	382
<b>Net Sales</b>	<b>35262</b>	<b>27953</b>	<b>70353</b>	<b>56175</b>	<b>114445</b>
Other Operating Income [See Note 3]	2229	775	3200	1293	4044
<b>Total Income</b>	<b>37491</b>	<b>28728</b>	<b>73553</b>	<b>57468</b>	<b>118489</b>
<b>Expenditure</b>					
(Increase) / Decrease in Stock in Trade	1731	(612)	1684	130	(1150)
Consumption of Raw / Packing Materials	8905	9074	20147	18139	37696
Purchase of Traded Goods	1030	1274	2150	2489	5429
Employees Cost	4001	3165	7866	6615	13299
Research and Development Expenses	2324	2678	5841	5166	10582
Depreciation and Amortisation	1052	899	2072	1689	3739
Other Expenditure	7709	7290	14174	12499	27293
<b>Total Expenditure</b>	<b>26752</b>	<b>23768</b>	<b>53934</b>	<b>46727</b>	<b>96888</b>
<b>Profit from Operations before Other Income, Interest and Exceptional Items</b>	<b>10739</b>	<b>4960</b>	<b>19619</b>	<b>10741</b>	<b>21601</b>
Other Income	65	194	278	285	336
<b>Profit before Interest and Exceptional Items</b>	<b>10804</b>	<b>5154</b>	<b>19897</b>	<b>11026</b>	<b>21937</b>
Net Borrowing Costs	592	574	907	1131	1944
<b>Profit after Interest but before Exceptional Items</b>	<b>10212</b>	<b>4580</b>	<b>18990</b>	<b>9895</b>	<b>19993</b>
Exceptional Items	-	-	-	-	(876)
<b>Profit from Ordinary Activities before tax</b>	<b>10212</b>	<b>4580</b>	<b>18990</b>	<b>9895</b>	<b>19117</b>
Tax Expense [See Note 4]	2180	152	9045	316	444
<b>Net Profit from Ordinary Activities after tax</b>	<b>8032</b>	<b>4428</b>	<b>9945</b>	<b>9579</b>	<b>18673</b>
Paid-up Equity Share Capital (Face Value of Rs.5)	4231	4231	4231	4231	4231
Reserves excluding Revaluation Reserves			-	-	69037
Basic and Diluted EPS for the period	9.49	5.23	11.75	11.32	22.07
Public shareholding					
Number of shares	24109500	24109500	24109500	24109500	24109500
Percentage of shareholding	28.49%	28.49%	28.49%	28.49%	28.49%
Promoters and promoter group Shareholding					
(a) Pledged/Encumbered					
- Number of shares	Nil	-	Nil	-	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	-	Nil	-	Nil
- Percentage of shares (as a% of the total share capital of the company)	Nil	-	Nil	-	Nil
(b) Non-encumbered					
- Number of shares	60501860	-	60501860	-	60501860
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	-	100.00%	-	100.00%
- Percentage of shares (as a% of the total share capital of the company)	71.51%	-	71.51%	-	71.51%

**Notes :**

- The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 31-Oct-09. There is no qualification in the Auditors Report on this statement of financial results.
- The Company operates a solitary business segment viz. pharmaceuticals, comprising mainly manufacture of branded formulations. A further breakdown of pharmaceutical sales is given below.

Particulars	Rs. in Lacs						
	Quarter Ended			Half Year Ended			Year Ended
	30-Sep-09	30-Sep-08	Growth %	30-Sep-09	30-Sep-08	Growth %	31-Mar-09
Domestic Formulations	18128	15764	15%	37993	32981	15%	62818
Exports	12251	8525	44%	22523	15861	42%	35470
Contract Manufacture	4884	3701	32%	9886	7430	33%	16385
Others	74	67	-	104	108	-	154
<b>Gross Sales</b>	<b>35337</b>	<b>28057</b>	<b>26%</b>	<b>70506</b>	<b>56380</b>	<b>25%</b>	<b>114827</b>
Less : Excise duty	75	104	-	153	205	-	382
<b>Net Sales</b>	<b>35262</b>	<b>27953</b>	<b>26%</b>	<b>70353</b>	<b>56175</b>	<b>25%</b>	<b>114445</b>

- Other operating income for the current quarter includes Rs 1603 lacs (previous quarter Rs 99 lacs) received pursuant to sale and license of self generated intellectual property rights related to drug products.
- (a) During the first quarter of the current financial year "MAT credit entitlement asset" of Rs 5286 lacs recognised in earlier years, was written-off based on amendments made in Income Tax Act 1961, and other relevant factors, and in terms of the "Guidance Note on Accounting for Credit Available in respect of MAT under the Income-tax Act, 1961" issued by the Institute of Chartered Accountants of India.  
  
(b) The Company has not recognised "MAT credit entitlement asset" in the current quarter and half year. The comparative quarter and half year includes such credit of Rs 491 lacs and Rs 1025 lacs respectively.
- During the current quarter, "Heunet Pharma GmbH" and "Norispharm GmbH" have been incorporated on 19-Aug-09 in Germany, as wholly owned subsidiaries of Torrent Pharma GmbH (a wholly owned subsidiary of Torrent Pharmaceuticals Ltd.).
- The Company made additional investment of Rs. 240 lacs during the current quarter in equity shares of Laboratorios Torrent, S.A. De C.V., its wholly owned subsidiary in Mexico.
- Status of investor complaints : Pending as of 01-Jul-09 - Nil, received during the quarter - 3, disposed off during the quarter - 2, pending as of 30-Sep-09 - 1.
- The Company has also prepared and published unaudited consolidated financial results for the quarter and half year ended, which were subjected to limited review by the statutory auditors of the Company.

**For TORRENT PHARMACEUTICALS LIMITED**

Date : 31-Oct-09

sd/  
**SAMIR MEHTA**  
Managing Director

.... Visit us at [www.torrentpharma.com](http://www.torrentpharma.com)....